The emergence and spread of new pathogens and the risk of bioterrorism represent continuous threats for human health. Vaccination can confer active and sustained protection, but the development of new vaccines is a slow process and vaccines are effective only in a preventive setting. The practice of administering polyclonal immunoglobulins from hyperimmune sera of animal or human origin, introduced by Behring and Kitasato 1 , has been used extensively in prophylactic as well as therapeutic settings 2 . However, there are several problems associated with the use of polyclonal sera, such as the antigenicity of heterologous proteins, the difficulty of finding immune donors, and risks related to the use of human blood products.
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Monoclonal antibodies represent an ideal alternative to hyperimmune sera 3 . Early work showed that human monoclonal antibodies can be produced by immortalizing B cells with Epstein-Barr virus (EBV) [4] [5] [6] or by fusing B cells with an appropriate partner to produce hybridomas 7, 8 . However, these methods have very low efficiency and therefore alternative strategies have been developed. These include (i) humanization of murine monoclonal antibodies through protein engineering 9 , (ii) selection of antibodies from phage-display libraries of human antibody fragments 10 and (iii) immunization of transgenic mice carrying human immunoglobulin loci, followed by production of monoclonal antibodies using hybridoma technology 11 . Although these methods have led to the development of several therapeutic monoclonal antibodies against cytokines or surface molecules, their impact on infectious disease therapy has been less pronounced 12 . Indeed, the number of therapeutic antibodies against infectious agents is still limited and only one is currently in use, to prevent respiratory syncytial virus (RSV) infection in newborns 13 .
The outbreak of SARS in March 2003 caused by SARS-CoV represents the most recent threat to human health [14] [15] [16] [17] . The virus is highly contagious and the clinical course is severe, with a high mortality rate [18] [19] [20] . Although the production of a vaccine remains a long-term goal, the benefits of vaccination can be expected only if a large proportion of the population is immunized. However, the low incidence of new cases of SARS suggests that large-scale vaccination may not be the best means of controlling disease spread.
During a SARS outbreak, passive serotherapy can potentially provide immediate protection against infection for contacts and medical personnel; a cure of infected individuals is also possible. Because human sera containing antibodies to SARS-CoV are not available in sufficient amounts, we considered the production of human monoclonal antibodies. Using an improved method of EBV transformation, we immortalized memory B cells from a patient who had recovered from SARS-CoV infection and isolated several monoclonal antibodies with high viral neutralizing activity in vitro and in vivo.
T E C H N I C A L R E P O R T S
of SARS-CoV infection of Vero cells. Serum collected from the patient at different time points after infection scored positive in all three assays (see Supplementary Table 1 online), whereas sera from uninfected individuals were nonreactive. Antibodies detected by ELISA and staining of spike-transfectants were highest at 2 months after infection and decreased to about one-third by 8 months. In contrast, neutralizing antibodies remained constant with a titer of 1/128. The isotype of the antibodies detected by ELISA and the spike-binding assay was IgG1 only.
Based on these data, we focused on IgG + memory B lymphocytes. These cells were isolated by a combination of magnetic and fluorescence-activated cell sorting and were immortalized with EBV in the presence of irradiated mononuclear cells 6 23 . We found that the addition of CpG 2006 increases the efficiency of B cell immortalization from 1-2% to 30-100%. Replicate cultures containing 10 IgG + memory B cells were set up and culture supernatants were analyzed for the presence of specific antibodies after 2 weeks ( Table 1 ). The fraction of cultures producing antibodies detected by ELISA was very high at 2 months after infection (virtually every second culture scored positive, consistent with a precursor frequency of~1 in 20) and decreased by 6 and 8 months. The frequency of cultures producing antibodies staining spike-transfected cells could be measured only at the 4, 6 and 8 months time points and was lower but more sustained. Most supernatants that stained spike-transfected cells showed neutralizing activity, but overall there was poor correlation between staining and neutralization (see Supplementary Fig. 1 ). These results indicate that only a small fraction of memory B cells specific for SARS-CoV antigens are directed against neutralizing epitopes present on the spike protein.
Isolation of monoclonal antibodies to SARS-CoV
EBV-B cells from cultures producing antibodies of the desired specificity were cloned by limiting dilution in the presence of irradiated mononuclear cells, with the addition of CpG 2006 to increase cloning efficiency. Out of 56 attempts, 43 (76%) led to the isolation of one or more clones producing antibodies of the selected specificity ( Table 2) . The EBV clones were stable, and monoclonal antibodies were recovered in the culture supernatant at concentrations of 3-20 µg/ml.
Several of the clones that scored positive by ELISA produced antibodies specific for the SARS nucleoprotein (NP), whereas others did not recognize NP but stained SARS-CoV-infected cells. As expected, none of these antibodies showed neutralizing activity.
Initial attempts to isolate neutralizing monoclonal antibodies were limited by the use of a viral neutralization assay that requires a biosafety level 4 laboratory. Nonetheless, a culture showing neutralization titer was identified from the first screening and cloned, and one resulting clone, S3.1, produces an IgG1,κ neutralizing monoclonal antibody. When purified from the culture supernatant and tested for its capacity to neutralize SARS-CoV, the S3.1 antibody neutralized 75 TCID 50 SARS-CoV at a concentration of ∼300 ng/ml, a potency up to 300-fold greater than that of convalescent serum (Fig. 1a) . Furthermore, S3.1 neutralized with the same efficiency both the Frankfurt and Urbani isolates (data not shown) and decorated the spikes of SARS-CoV as detected by immunoelectron microscopy (Fig. 1b) .
The later availability of SARS-CoV spike transfectants provided an efficient prescreening method. Approximately 50% of the antibodies staining spike-transfected cells also neutralized the homologous virus.
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VOLUME We isolated 35 monoclonal antibodies that neutralized SARS-CoV (see examples in Table 2 and Supplementary Fig. 1 ). Some efficiently stained transfectants at low immunoglobulin concentrations, consistent with high-avidity binding, and showed a neutralizing titer proportional to the level of staining. In contrast, other antibodies stained poorly and only at high immunoglobulin concentrations, consistent with low-avidity binding, but showed efficient neutralization, even at immunoglobulin concentrations at which spike staining was hardly detectable. The final antibody concentration capable of completely neutralizing SARS-CoV infection in vitro ranged from 850 to 1 ng/ml ( Table 2) . These results show that the method described for improved EBV immortalization can rapidly produce a battery of human monoclonal antibodies with potent neutralizing capacity in the subnanomolar range.
S3.1 antibody inhibits SARS-CoV infection in mice
The in vivo neutralizing activity of S3.1 antibody was tested in a mouse model of acute SARS-CoV infection 24 . Graded amounts of purified S3.1 monoclonal antibody were transferred to naive mice by intraperitoneal injection to determine whether antibody alone could prevent replication of SARS-CoV in the respiratory tract. A human IgG1 monoclonal antibody of irrelevant specificity (M12) was used as a negative control. After 2 d, the mice received an intranasal challenge dose of 10 4 TCID 50 of SARS-CoV ( Table 3 ). Mice that received S3.1 monoclonal antibody were protected from replication of challenge virus, particularly in the lower respiratory tract. Significant (P < 0.05) restriction of virus replication in the upper respiratory tract was noted in those mice that received the highest dose of S3.1 monoclonal antibody. These results show that improved EBV transformation of memory B cells can lead to rapid and efficient isolation of candidate therapeutic monoclonal antibodies.
DISCUSSION
In this study we have demonstrated an improved method of B cell immortalization by EBV involving the addition of a polyclonal B cell activator, and we have shown that with this method it is possible to interrogate the memory B cell repertoire of a SARS convalescent patient and to isolate with high efficiency B cell clones producing neutralizing monoclonal antibodies. This procedure is rapid--it can be completed in less than 3 months--and allows screening of a large repertoire of antigen-specific memory B cells for those with the most favorable affinity and specificity.
A high proportion of antigen-specific peripheral blood memory B cells, such as that found in the SARS convalescent patient, is not a prerequisite for the isolation of human monoclonal antibodies. Indeed, memory B lymphocytes are maintained through an individual's lifetime at levels that correlate with sustained serum antibody concentrations 23 . Consequently, the memory B cell pool can be interrogated at any time after priming, with the only limiting factor being the total number of cells that need to be screened to access enough specificities. As an example, we have been able to isolate neutralizing monoclonal antibodies specific for measles virus from a blood sample obtained 47 years after infection (E.T., unpublished data).
The high efficiency of EBV immortalization and cloning obtained in the presence of a polyclonal activator were instrumental in the isolation of several monoclonal antibodies specific for SARS-CoV. Most of the monoclonal antibodies we isolated using ELISA recognized NP or other viral proteins, but did not neutralize the virus. Indeed, the fraction of memory B cells that recognized denatured viral proteins exceeded by 5-to 10-fold the fraction of B cells that recognized the native spike protein. Furthermore, only 50% of the antibodies that stained spike-transfected cells showed neutralizing activity, possibly because they recognized epitopes that are not available on the spike trimers. These findings indicate that most of the human B cell response is directed against nonprotective epitopes. Initial screening for neutralizing antibodies led to the isolation of the S3.1 clone, the only clone tested in an animal model. The subsequent development of a spike-binding assay allowed much more rapid identification of neutralizing candidates and led to the isolation of antibodies with neutralizing capacity up to 300-fold higher. When neutralizing monoclonal antibodies were compared for spike staining and neutralizing activity, two patterns emerged (Fig. 2) . Some antibodies showed high-avidity binding to spike transfectants and a neutralizing titer proportional to the degree of binding. In contrast, other antibodies showed low-avidity binding in spite of efficient viral neutralization. It is possible that the former recognize exposed epitopes within the receptor binding S1 domain of the spike protein, whereas the latter recognize epitopes within the S2 domain, which is exposed only during viral fusion and may be poorly accessible in transfected cells 25 . An alternative possibility is that spike molecules may be differentially assembled in viral particles compared to BHK cells. This may explain the lack of correlation between staining and neutralization, as well as the finding that most antibodies neutralized virus at concentrations at which staining was hardly detectable. Further studies, including assessment of direct binding to viral particles, analysis of escape mutants 25 and epitope mapping using synthetic peptides, will be required to elucidate how antibodies to the spike protein neutralize SARS-CoV infection.
The in vivo neutralizing activity of the S3.1 monoclonal antibody was tested in a mouse model of acute SARS infection 24 . Intraperitoneal injection of as little as 20 µg of S3.1 antibody completely protected mice from viral replication in the lower respiratory tract, whereas restriction of virus replication was observed in the upper respiratory tract. The observation that viral replication was more effectively prevented in the lower respiratory tract than in the upper respiratory tract is consistent with findings in similar passive transfer experiments with influenza A viruses and respiratory syncytial virus 26, 27 .
In conclusion, we have described a method for the rapid and efficient isolation of neutralizing antibodies to an emerging pathogen. This method offers two unique features: First, the antibodies are produced by immortalization of memory B lymphocytes, which are stable over a lifetime and can easily be isolated from peripheral blood. This bypasses the need for antigen boosting required for the generation of hybridomas. Second, the antibody is isolated from a primed natural host who has survived the natural infection, eliminating the need for immunization of experimental animals, which may show different susceptibility and, therefore, different immune responses. This method delivers large numbers of antibodies that can immediately be selected for the most favorable profile according to criteria such as affinity, epitope specificity and propensity to generate escape mutants. ELISA. The Frankfurt isolate of the SARS-CoV (GenBank accession number AY310120) was provided by H.-W. Doerr (University of Frankfurt). Cell culture supernatant of infected Vero cells was collected, clarified by centrifugation at 3,000 r.p.m. for 5 min and then centrifuged through a 20% sucrose cushion at 20,000 r.p.m. for 2 h in a Beckman SW28 rotor. The pellet was purified using a potassium tartrate/glycerol gradient and resuspended in 500 µl TNE buffer (10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 2 mM EDTA) to a protein concentration of approximately 0.5 mg per ml 28 . The antigen suspension used for ELISA was prepared by adding 1% SDS to the viral pellet and boiling the mixture for 10 min. ELISA plates (Nunc) were coated with SARS-CoV antigen in 0.1 M sodium phosphate buffer (pH 7). Serial dilutions of serum or antibody supernatants were added for 2 h and the antibody bound was revealed using isotypespecific secondary antibodies coupled to alkaline phosphatase.
METHODS
In vitro neutralization assay. Sera or culture supernatants were diluted in 2-log steps and 25 µl was mixed with an equal volume of medium containing 75 TCID 50 SARS-CoV (virus titer was determined according to the method of Karber 29 ). Mixtures were allowed to sit 45 min at room temperature, and then 50 µl of Vero cells (1.5 × 10 5 per ml) were added and the cultures incubated for 3 d at 37 °C. All assays were performed in a biosafety level 4 laboratory. As neutralization titer we indicate the last antibody dilution that completely prevents the cytopathic effect of SARS-CoV. As neutralizing antibody concentration we indicate the final antibody concentration (ng/ml) in the cultures at which complete protection was observed.
Transient expression of the spike protein of SARS-CoV. cDNA was prepared from total SARS-CoV RNA using random primers. The coding region of the spike protein was amplified by PCR. The forward and reverse PCR primers overlap 20 nucleotides of 5′ and 3′ termini, respectively, of the spike protein coding region (GenBank accession number AY310120). To ensure translation in eukaryotic cells, a canonical Kozak sequence (5′-GCCGCCACC-3′) was included in front of the protein's start codon. The amplified fragment was inserted into an alphavirus vector as described 30 . The recombinant plasmid VCR-SSP was transcribed in vitro using the mMESSAGE mMACHINE kit (Ambion). The RNA obtained from 2 µg of the plasmid DNA in a 20-µl reaction was mixed with 20 million BHK cells in 1 ml of PBS. Cells were electroporated using GenePulser (Bio-Rad) twice under the condition of 1,650 V/25 874 VOLUME 10 | NUMBER 8 | AUGUST 2004 NATURE MEDICINE Figure 2 Binding and neutralization capacity of monoclonal antibodies specific for SARS-CoV spike. Shown is the staining of BHK cells transfected with SARS-CoV spike mRNA by serial dilutions of ten neutralizing monoclonal antibodies. The symbols indicate the neutralizing titer: that is, the antibody dilution added in the neutralization assay that gave complete viral neutralization.
